[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.255.49. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1959

Muscular Dystrophy: IX. Body Growth, Muscle Strength, and Serum Solutes During Methyltestosterone-KCl Therapy

Author Affiliations

Pittsburgh

AMA Am J Dis Child. 1959;97(4):439-444. doi:10.1001/archpedi.1959.02070010441009
Abstract

Though androgenic steroids have been administered in muscular dystrophy without obvious clinical benefit,1,2 it is conceivable that such therapy might nonetheless ameliorate the course of this disease. This is not an unreasonable possibility in view of the well-established protein anabolic3,4 and musculotrophic properties5-8 of such agents and the recognized variability in the rate of physical deterioration in this condition which might mask less dramatic though nonetheless beneficial effects. It was felt that such trials would necessitate pharmacologic dosages of an androgenic steroid, since no evidence of a deficiency of endogenous androgens in childhood or juvenile muscular dystrophy has appeared to date. It is well recognized, of course, that disturbances of gonadal and adrenocortical steroid production and other endocrinopathy may be a frequent feature of another form of muscular dystrophy, i. e., in dystrophia myotonica or Steinert's disease.9,10

Materials and Methods  Thirteen boys and two adults with

×